Cancer treatment is complex, and for many patients, radiation therapy is a critical part of their care journey. Yet the delivery of radiation therapy—how much is given, how often, and with what level of precision—can vary widely across providers, with meaningful implications for outcomes, side effects, and overall patient experience.
The Michigan Radiation Oncology Quality Consortium (MROQC) was founded in 2011 in partnership with Blue Cross Blue Shield of Michigan (BCBSM) to better understand and reduce variation in radiation therapy practices across Michigan - specifically related to the use of advanced technologies such as 3D conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in breast and lung cancer treatment. The BCBSM-funded CQIs play a crucial role in driving healthcare quality improvement in Michigan. MVC is excited to continue highlighting the innovative contributions of individual CQIs like MROQC and the ways in which MVC’s data support high-value care initiatives across the portfolio.
At the time of MROQC’s founding, there was growing interest in understanding how these technologies were being used across institutions and ensuring that newer, more complex approaches were being applied appropriately and consistently. By bringing radiation oncology providers together in a statewide collaborative, MROQC created a platform to compare treatment patterns, share best practices, and evaluate how different approaches affected patient outcomes. Over time, the work of MROQC expanded beyond treatment utilization to focus on broader quality improvement and value-based care initiatives. Today, the consortium supports multiple disease-site quality initiatives, collects patient-reported outcomes, and collaborates with clinicians and health system partners to improve the safety, effectiveness, and patient-centeredness of radiation therapy across Michigan.
Services and Benefits to MROQC Members
One of the most unique aspects of MROQC is its strong culture of collaboration across institutions that would traditionally be competitors. Radiation oncologists, medical physicists, nurses, dosimetrists, radiation therapists, abstractors, and administrators from across Michigan work together to analyze data, identify opportunities for improvement, and implement changes that benefit patients statewide. It is through this collaborative infrastructure that MROQC supports radiation oncology providers, hospitals, and care teams across Michigan.
Members benefit from:
- Participation in statewide quality improvement initiatives across multiple disease sites
- Access to real-time performance dashboards and benchmarking data
- Collaborative working groups where clinicians share best practices and develop new quality measures
- Educational opportunities and training resources
- Support for research, publications, and national presentations
- Participation in innovative incentive programs such as the BCBSM Gold Card program, which reduces prior authorization burden for high-performing facilities.
Through this collaborative model, the MROQC Coordinating Center team (Figure 1) enables clinicians and institutions to learn from each other, implement best practices more quickly, and continuously improve patient care. This has allowed Michigan to become a national leader in radiation oncology quality improvement, demonstrating how data-driven partnerships between member providers and payers can improve outcomes, reduce costs, and enhance patient experience.
Figure 1. MROQC Coordinating Center Team
MROQC’s Key Initiatives and Achievements
Several initiatives highlight how MROQC’s collaborative model has been translated into meaningful improvements for patients and providers across Michigan.
Expanding use of shorter, evidence-based radiation treatments
MROQC has helped increase the adoption of hypofractionated radiation therapy, which delivers effective treatment in fewer sessions. For example, the use of accelerated whole breast radiation therapy has increased by more than 60% statewide, reducing treatment burden for patients while maintaining excellent outcomes.
Similarly, initiatives promoting shorter treatment courses for bone metastases have helped 78% of MROQC patients receive effective pain relief with fewer visits to the clinic, improving quality of life while reducing healthcare costs.
Improving treatment safety by reducing radiation exposure to critical organs
Through collaborative treatment planning initiatives, MROQC members have worked to reduce radiation exposure to organs such as the heart and esophagus during cancer treatment. These efforts have helped lower the risk of treatment-related complications and improve the safety of radiation therapy across the state.
Reducing administrative burden through the Gold Card program
In partnership with BCBSM, MROQC helped develop and implement the Gold Card program in 2017, which allows high-performing radiation oncology facilities to receive automatic prior authorization approval for radiation therapy treatments. This program rewards facilities that consistently meet quality improvement criteria and has significantly reduced administrative burden while allowing clinicians to begin treatment more quickly for patients.
Together, these successes demonstrate how statewide collaboration and real-world data can drive improvements in patient outcomes, treatment efficiency, and value-based care (Figure 2).
Figure 2. MROQC Performance: The Right Treatment at the Right Time
MROQC’s current initiatives focus on advancing high-value radiation therapy while strengthening the data infrastructure needed to support statewide quality improvement. Across its disease-site working groups - breast, lung, prostate, and metastatic cancer - MROQC continues to promote initiatives that improve treatment quality, reduce variation in care, and support evidence-based practice. Current efforts include improving treatment planning standards, expanding the use of shorter radiation therapy courses when appropriate, and monitoring treatment safety measures that reduce toxicity and improve patient outcomes.
MROQC is also expanding its quality improvement work to include brain metastases, building on the success of the existing metastases working group. This effort will help better understand treatment patterns and outcomes for patients receiving radiation therapy for brain metastases and identify opportunities to standardize and improve care.
For prostate cancer, MROQC partners with the Michigan Urological Surgery Improvement Collaborative (MUSIC) to better understand care across the full patient journey - from diagnosis through treatment. This collaboration allows the teams to link data across specialties and identify opportunities to improve coordination and outcomes for prostate cancer patients across Michigan.
Together, these initiatives ensure that MROQC continues to support clinicians across Michigan with the data, collaboration, and infrastructure needed to improve radiation therapy care for patients statewide.
Addressing Non-Medical Drivers of Health Outcome Variation
Another important focus area is improving access to care for all Michigan cancer patients. MROQC is addressing variation in care through both data collection and targeted quality improvement efforts. The consortium collects data on demographic and social factors that may influence access to care or treatment outcomes. These data allow the collaborative to identify patterns of variation across facilities and patient populations and develop targeted interventions to address those outcome gaps. In addition, MROQC established the M-EQUAL committee, which focuses specifically on improving access to high-quality cancer care. The committee works to expand non-medical drivers of care data collection, is aiming to develop barriers-to-care quality measures and provides education and resources to member institutions to improve access and outcomes for all patients. Ultimately, MROQC’s efforts to leverage statewide data with collaborative learning translate into tangible benefits for patients: shorter and more convenient treatment courses, fewer complications, and more consistent care regardless of where they are treated.
Looking Ahead: Strengthening Data Infrastructure and Member Engagement
MVC and MROQC are currently partnering to explore a new data opportunity using claims-based analysis. This effort is looking to evaluate whether reduced fraction palliative radiotherapy for painful bone metastases among MROQC-participating sites results in lower overall healthcare utilization compared to episodes of care attributed to non-MROQC sites.
MROQC knows from experience that quality improvement requires more than collecting data - it requires building trust among clinicians, ensuring data accuracy, and creating opportunities for teams to learn from one another. Over the years, MROQC has seen how powerful a collaborative model can be when clinicians across institutions come together around shared goals. That is why the MROQC Coordinating Center continues to strengthen member engagement and is investing heavily in data infrastructure and reporting tools to support the collaborative with trustworthy, accurate data. These efforts include improving dashboards and reporting capabilities for participating facilities and preparing for a transition to a more scalable data platform to support future growth, analytics, and research. Visit the MROQC website to learn more about its team, offerings, and successes.